SARS-COV-2 Spike RBD PaB 

To Order Contact us: stephen@expresspharmapulse.com

SARS-CoV-2 Spike RBD Nanobody

A73680-050 50 ul Ask for price

SARS-CoV-2 Spike RBD Nanobody

A73680-100 100 ul
EUR 882.2

SARS-CoV-2 Spike RBD Nanobody

A73680
  • Ask for price
  • EUR 882.20
  • 50 ul
  • 100 ul

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)

100684-2 50 µg
EUR 435
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)

100696-2 1 mg
EUR 3200
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)

100938-2 50 µg
EUR 555
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag

E80024-2 1 ml
EUR 4995.1

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion

E80026-2 50 ul
EUR 823.9

Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2)

100698-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2)

100769-2 1 mg
EUR 2500
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2)

100846-2 1 mg
EUR 2600
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike (SARS-CoV-2) Lentivirus

78010-2 500 µl x 2
EUR 2095
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial

E80028
  • EUR 388.30
  • EUR 860.20
  • 20 ul
  • 100 ul

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag

E80023-2 1 ml
EUR 3934.7

Spike S1 RBD, Avi-His-tag, Biotin-labeled (SARS-CoV-2)

100697-2 50 µg
EUR 480
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD, His-Avi-Tag, Biotin-Labeled (SARS-CoV-2)

100937-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This construct contains a C-terminal His-tag (6xHis) followed by an Avi-Tag. The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

Spike RBD (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2)

100977-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, originally discovered in the United Kingdom, and contains mutation N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Spike RBD (B.1.351 Variant) Avi-His-Tag (SARS-CoV-2)

100978-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.351, orignally discovered in South Africa and contains mutations K417N, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification and shows less than 5% aggregation in gel filtration. 

SARS-CoV-2 (COVID-19) Spike RBD Antibody

9087-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody

9087-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Spike S1 RBD, His-tag (SARS-CoV-2)

100687-1 50 µg
EUR 410
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa.

Spike S1 RBD, Fc fusion (SARS-CoV-2)

100699-1 50 µg
EUR 410
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag

E80025-2 1 ml
EUR 3934.7

Spike S1 RBD, Fc-Fusion, Avi-Tag, Biotin-labeled (SARS-CoV-2)

100695-2 50 µg
EUR 435
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90% MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (K417T, E484K, N501Y), Avi-His-Tag (SARS-CoV-2)

100993-2 1 mg
EUR 2995
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to the RBD of SARS-CoV-2 Variant P.1, originally discovered in Brazil, and contains the three mutations  K417T, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following affinity purification.

Spike S1 RBD (B.1.617 Variant), Avi-His-Tag (SARS-CoV-2)

101156-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally identified in India, and contains mutations L452R and E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag

E80021
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

Spike S1, Fc fusion (SARS-CoV-2)

100688-2 50 µg
EUR 505
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa.

Anti-Spike S1 Antibody (SARS-CoV-2)

100715-2 100 µg
EUR 440
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike S2, Fc-Tag (SARS-CoV-2)

100895-2 500 µg_x000D_
EUR 1815
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa.

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag

E80020
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag

E80022
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

10-100 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

10-117 0.1 mg
EUR 752.1
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

10-204 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

10-206 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

10-303 0.1 mg
EUR 632.4
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein

SARS-CoV-2 (COVID-19) Spike-RBD Recombinant Protein

10-008 0.1 mg
EUR 714.3
Description: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS CoV-2 spike protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on the target cells. SARS-CoV-2 spike protein (RBD) has the potential value for the diagnosis of the virus.

SARS-CoV-2 (COVID-19) Spike-RBD Recombinant Protein

10-015 0.1 mg
EUR 714.3
Description: SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS CoV-2 spike protein is composed of S1 domain and S2 domain. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on the target cells. SARS-CoV-2 spike protein (RBD) has the potential value for the diagnosis of the virus.

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)

9087-biotin-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin)

9087-biotin-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 Spike RBD protein antibody pair 1

CSB-EAP33245 1 pair
EUR 900
Description: This is a set of capture antibody and HRP-conjugated antbody for quantitative detection of SARS-CoV-2 Spike RBD protein for through solid phase sandwich ELISA.

Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2)

100684-1 20 µg
EUR 295
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Avi-His-tag (SARS-CoV-2)

100696-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)

100938-1 20 µg
EUR 420
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2)

100938-3 100 µg
EUR 740
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa.

Spike S1 RBD (V367F), Avi-His-tag Biotin-labeled (SARS-CoV-2) HiP™

100770-2 50 µg
EUR 435
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

79942-2 500 µl x 2
EUR 4405
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

79981-2 500 µl x 2
EUR 5245
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

SARS-CoV-2 (COVID-19) Biotinylated Spike RBD Recombinant Protein

10-205 0.1 mg
EUR 752.1
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein

10-304 0.1 mg
EUR 632.4
Description: SARS-CoV-2 (COVID-19) Spike RBD + SD1 Recombinant Protein

SARS-CoV-2 (COVID-19) Spike RBD domain Recombinant Protein

20-232 0.1 mg
EUR 726.9
Description: SARS-CoV-2 (COVID-19) Spike RBD domain Recombinant Protein

Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant

P1530-10 10 µg
EUR 187.2

Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant

P1530-50 50 µg
EUR 709.2

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B5]

SD9431-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B5]

SD9431-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B7]

SD9433-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T4P3-B7]

SD9433-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T5P8-F9]

SD9503-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T5P8-F9]

SD9503-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T5P7-G12]

SD9505-002mg 0.02 mg
EUR 253.22
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike RBD Antibody [T5P7-G12]

SD9505-01mg 0.1 mg
EUR 723.62
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag

E80024-1 100 ul
EUR 635.8

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion

E80026-1 20 ul
EUR 588.5

Recombinant SARS-CoV-2 Spike RBD Protein with His-Tag

E80000-1 100 ul
EUR 518.1

Recombinant SARS-CoV-2 Spike RBD Protein with mFc Tag

E80011-1 100 ul
EUR 588.5

Recombinant SARS-CoV-2 Spike RBD Protein with His-Tag

E80015-1 100 ul
EUR 695.2

Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2)

100698-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2)

100769-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2)

100846-1 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (G476S), Avi-His-tag (SARS-CoV-2)

100868 100 µg
EUR 320
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with G476S mutation and with a C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD (B.1.617.2, Delta Variant), Avi-His-Tag (SARS-CoV-2) HiP™

101153-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations L452R and T478K. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

SARS-CoV-2 Spike Peptide

9083P 0.05 mg
EUR 235.5
Description: (NT) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide

9087P 0.05 mg
EUR 235.5
Description: (CT) SARS-CoV-2 Spike RBD peptide

SARS-CoV-2 Spike Peptide

9091P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide

9095P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

Spike (SARS-CoV-2) Lentivirus

78010-1 100 µl
EUR 835
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial

E80028-2 100 ul
EUR 860.2

Spike Trimer (S1+S2), His-tag (SARS-CoV-2)

100728-2 1 mg
EUR 2995
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa.

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)

78028-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.
The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (eGFP Reporter)

78035-2 500 µl x 2
EUR 5145
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.

The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag

E80027
  • EUR 635.80
  • EUR 4087.60
  • 1 ml
  • 100 ul

SARS-CoV Spike Antibody

3219-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3219-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3221-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3221-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3223-002mg 0.02 mg
EUR 206.18
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3223-01mg 0.1 mg
EUR 523.7
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3225-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3225-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Protein

abx060655-1mg 1 mg
EUR 2030.4

SARS-CoV-2 (COVID-19) Spike RBD + SD1 +SD2 Recombinant Protein

10-305 0.1 mg
EUR 632.4
Description: SARS-CoV-2 (COVID-19) Spike RBD + SD1 +SD2 Recombinant Protein

Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; RBD), Recombinant

P1529-10 10 µg
EUR 235.2

Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; RBD), Recombinant

P1529-50 50 µg
EUR 709.2

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag

E80023-1 100 ul
EUR 635.8

Spike S1 RBD, Avi-His-tag, Biotin-labeled (SARS-CoV-2)

100697-1 25 µg
EUR 325
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike S1 RBD, His-Avi-Tag, Biotin-Labeled (SARS-CoV-2)

100937-1 20 µg
EUR 295
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This construct contains a C-terminal His-tag (6xHis) followed by an Avi-Tag. The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.

Spike RBD (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2)

100977-1 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, originally discovered in the United Kingdom, and contains mutation N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification.

Spike RBD (B.1.351 Variant) Avi-His-Tag (SARS-CoV-2)

100978-1 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.351, orignally discovered in South Africa and contains mutations K417N, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification and shows less than 5% aggregation in gel filtration. 

Spike RBD (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit

78018 96 rxns.
EUR 600
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection._x000D_
The Spike RBD (SARS-CoV-2):ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike RBD protein is attached to a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike RBD on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce color, which can then be measured using a UV/Vis spectrophotometer microplate reader.

ACE2:Spike RBD (SARS-CoV-2) Inhibitor Screening Colorimetric Assay Kit

78031 96 rxns.
EUR 630
Description: Coronavirus disease 2019 (COVID-19) increases the risk of developing Acute Respiratory Distress Syndrome (ARDS), which is often fatal at the late stages of the infection when the SAR-CoV-2 virus causes significant damage to the lungs. As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein receptor binding domain (RBD) recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection.The ACE2:SARS-CoV-2 Spike (RBD) Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is the high sensitivity of detection of Fc-tagged Spike protein by HRP-labeled Anti-mouse-Fc. Only a few simple steps on a microtiter plate are required for the assay. First, ACE2 protein is attached to a clear nickel-coated 96-well plate. Next, SARS-CoV-2 Spike-Fc is incubated with ACE2 on the plate. Finally, the plate is treated with HRP-labeled anti-Fc, followed by addition of an HRP substrate to produce color, which can then be measured using a UV/Vis spectrophotometer microplate reader.

Spike S1 RBD (SARS-CoV-2): ACE2 Inhibitor Screening Assay Kit

79931 96 rxns.
EUR 675
Description: The SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is the high sensitivity of detection of bound His-labeled ACE2 by HRP-labeled Anti-His. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-2 Spike is coated on a 96-well plate. Next, ACE2-His is incubated with SARS-CoV-2 Spike on the plate. Finally, the plate is treated with Anti-His-HRP followed by addition of an HRP substrate to produce chemiluminescence, which then can be measured using a chemiluminescence reader.

ACE2: Spike S1 RBD (SARS-CoV-2) Inhibitor Screening Assay Kit

79936 96 rxns.
EUR 660
Description: The ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is the high sensitivity of detection of bound Fc-tagged Spike protein by HRP-labeled Anti-Fc. Only a few simple steps on a microtiter plate are required for the assay. First, ACE2 protein is attached to a nickel-coated 96-well plate. Next, SARS-CoV-2 Spike-Fc is incubated with ACE2 on the plate. Finally, the plate is treated with Anti-Fc-HRP followed by addition of an HRP substrate to produce chemiluminescence, which then can be measured using a chemiluminescence reader.

SARS Spike RBD Recombinant Protein

10-211 0.1 mg
EUR 651.3
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Spike Trimer (S1+S2), His-tag (SARS-CoV)

100789-2 500 µg_x000D_
EUR 1900
Description: Severe acute respiratory Coronavirus SARS Coronavirus Spike trimer (S1+S2) (SARS-CoV S protein), Genbank Accession No. AAP13567, a.a. 1-1195(full length), with a C-terminal His-tag, expressed in a HEK293 expression system. MW=136 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)

78614-2 500 µl x 2
EUR 4320
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).

Spike S1 (16-685), Avi-His-tag (SARS-CoV-2)

100730-2 1 mg
EUR 2720
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685 with a C-terminal Avi-His-tag, expressed in a HEK293 expression system, MW=78 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2)

100992-2 1 mg
EUR 2850
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. 

Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)

78112-2 500 µl x 2
EUR 4405
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_

Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

78637-2 500 µl x 2
EUR 3995
Description: The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3.The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices.

Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)

79982-2 500 µl x 2
EUR 8110
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_
The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_

Spike S1 RBD (B.1.1.7; Alpha Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™

100999-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, also known as variant Alpha originally identified in the United Kingdom, and contains mutation N501Y. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 RBD (B.1.617.2, Delta Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™

101154-2 50 µg
EUR 455
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations L452R and T478K. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate

79952-2 10 mg
EUR 3460
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹.

SARS-CoV-2 Spike S2 Peptide

9119P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike S2 Peptide

9123P 0.05 mg
EUR 235.5
Description: (CT) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Monoclonal Antibody

A73664-050 50 ul
EUR 341

SARS-CoV-2 Spike Monoclonal Antibody

A73664-100 100 ul
EUR 518.1

SARS-CoV-2 Spike Monoclonal Antibody

A73664
  • EUR 341.00
  • EUR 518.10
  • 50 ul
  • 100 ul

Spike S1 RBD (B.1.617.2.1, Delta Plus Variant), Avi-His-Tag, Biotin-Labeled (SARS-CoV-2) HiP™

101182-2 50 µg
EUR 435
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains RBD mutations K417N, L452R and T478K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

SARS-CoV-2 (COVID-19) Variant Spike Protein RBD (E484D) Recombinant Protein

21-829 0.1 mg
EUR 714.3
Description: SARS-CoV-2 (COVID-19) Variant Spike Protein RBD (E484D) Recombinant Protein

Human CellExp™ SARS-CoV-2 Spike Protein (RBD 310-568), Recombinant

P1543-10 10 µg
EUR 187.2

Human CellExp™ SARS-CoV-2 Spike Protein (RBD 310-568), Recombinant

P1543-50 50 µg
EUR 576

Human CellExp™ SARS-CoV-2 Spike Protein (RBD; 331-524), Recombinant

P1544-10 10 µg
EUR 187.2

Human CellExp™ SARS-CoV-2 Spike Protein (RBD; 331-524), Recombinant

P1544-50 50 µg
EUR 576

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag

E80025-1 100 ul
EUR 635.8

Spike S1 RBD, Fc-Fusion, Avi-Tag, Biotin-labeled (SARS-CoV-2)

100695-1 25 µg
EUR 295
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90% MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 RBD, Fc-Fusion, Avi-Tag, Biotin-labeled (SARS-CoV-2)

100695-3 200 µg
EUR 1500
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90% MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

SARS-CoV-2 IgG Detection Kit (Colorimetric Anti-Spike RBD IgG detection)

79985 96 rxns.
EUR 590
Description: The SARS-CoV-2 IgG detection kit is designed for qualitative detection of human IgG antibodies in serum collected from individuals suspected of prior infection with the virus that causes COVID-19. This fast and simple ELISA uses the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein (BPS Bioscience #100696) to identify IgG antibodies that indicate a previous infection with SARS-CoV-2. 

Spike S1 RBD (K417T, E484K, N501Y), Avi-His-Tag (SARS-CoV-2)

100993-1 100 µg
EUR 335
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to the RBD of SARS-CoV-2 Variant P.1, originally discovered in Brazil, and contains the three mutations  K417T, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following affinity purification.

Spike S1 RBD (B.1.617 Variant), Avi-His-Tag (SARS-CoV-2)

101156-1 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally identified in India, and contains mutations L452R and E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Spike S1 RBD (B.1.618 Variant), Avi-His-Tag (SARS-CoV-2)

101158 100 µg
EUR 320
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.618 originally identified in India, and contains mutation E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. 

Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)

78625-2 500 µl x 2
EUR 4510
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K

Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

78626-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1 (B.1.1.529), BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 BA.2 Variant Spike (Genbank Accession #QHD43416.1 containing all the BA.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2 Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag

E80021-2 1 ml
EUR 4276.8

Spike S1 (13-665), Fc Fusion, Avi-tag (SARS-CoV-2)

100678-2 1 mg
EUR 3000
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2)

100719-2 1 mg
EUR 2720
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)

78142-2 500 µl x 2
EUR 4320
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_

Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)

78143-2 500 µl x 2
EUR 4195
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_

Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)

78144-2 500 µl x 2
EUR 4195
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_

Spike (B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

78158-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. The United Kingdom (UK) identified a variant called B.1.1.7 with a large number of mutations in the fall of 2020. This variant spreads more easily and quickly than other variants.
The Spike (B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.7 variant Spike (Genbank Accession #QHD43416.1 with B.1.1.7 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP fluorescence. The Spike (B.1.1.7 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.7 variant in a Biosafety Level 2 facility.

Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

78159-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection.
In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with P.1 mutations, see below for details) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility.

Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

78160-2 500 µl x 2
EUR 4195
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection.
A variant called B.1.351 was first identified in the fall of 2020 in the Republic of South Africa. This South African variant, also known as 501Y.V2, has many mutations that may lead to higher transmissibility and infectivity. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (B.1.351) variant in a Biosafety Level 2 facility.

Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)

78642-2 500 µl x 2
EUR 3995
Description: The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 D614G variant in a Biosafety Level 2 facility.The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells.

SARS-COV-2 Spike RBD PaB